Thrombin Market Scope
Thrombin is a serine protease, an enzyme that, in humans, is encoded by the F2 gene. Thrombin is available in many forms as a hemostatic agent and has been purified from numerous sources and classified according to the plasma used to create it. Thrombin has high growth prospects owing to the rising prevalence of blood clotting disorders and increasing surgical activities.
The market study is being classified by Type (Bovine Thrombin, Human Thrombin and Recombinant Thrombin) and major geographies with country level break-up.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Thrombin market throughout the predicted period.
Pfizer (United States), Johnson & Johnson Servicess, Inc. (United States), Octapharma AG (Switzerland), Baxter International Inc. (United States), Bayer AG (Germany), CSL Limited (Australia), Grifols, S.A. (Spain), GE Healthcare (United States) and Hualan Biological (China) are some of the key players profiled in the study.
AdvanceMarketAnalytics has segmented the market of Global Thrombin market by Type, Application and Region.
On the basis of geography, the market of Thrombin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In July 2019, Pfizer Inc. announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough science for the discovery, development, and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
In Dec 2018, Baxter International Inc.announced the introduction of the Disposable Curved Applicator, which enhances the delivery experience of its Floseal Hemostatic Matrix product line for procedures in the otolaryngology, head, and neck surgical specialty. Floseal Matrix contains Thrombin made from human plasma.
- Rising Adoption of Smoking increasing the Prevalence of Thrombosis
- Growing Prevalence of Blood Clotting Disorders
- Growth in the Use of Thrombin due to Adoption of Hemostats in Excessive Bleeding during Surgical Procedure
- Increasing Surgical Procedure due to Increasing Number of Diseases Worldwide
- Growth and Advancement in Technology in the Healthcare Industry in Developing Countries
- Starigent Govermanebt Regulation
- Ineffective in Patients who Suffer from Afibrinogenemia
Key Target AudienceThrombin Suppliers/Distributors, Potential Investors, Healthcare Industry and Research and Development Organisation
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase